CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and a rating upgrade by a Wall Street analyst. Though CRSP’s quarterly ...

Cathie Wood’s ARK ETFs capitalized on the pullback in Coinbase (COIN) and Robinhood (HOOD) stocks to load up additional shares on Thursday ...

Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store. The rise in CRISPR Therapeutics' share price can be ...

According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $74.50. Shares of CRSP opened at $49.72 on Friday. The stock has a market cap of ...

But for what it's worth, Wall Street likes what it sees on the R&D side, with Citigroup ranking CRSP stock a "buy" and a consensus price target that is roughly 50% higher than current levels.

Let’s delve into the company’s strengths and weaknesses to gain a better understanding of how to play the stock amid this price rise. CRSP/VRTX’s Strong Global Launch Efforts for Casgevy The ...